ABC transporter gene expression in benign and malignant ovarian tissue
- PMID: 19922990
- DOI: 10.1016/j.ygyno.2009.10.077
ABC transporter gene expression in benign and malignant ovarian tissue
Abstract
Objective: ATP-binding Cassette (ABC) transporters are thought to cause multiple drug resistance (MDR) in various carcinomas. Gene expression data from individual transporters in ovarian cancer tissue is contradictory and also scarce for some of them. RNA levels of a panel of ABC transporters were collected and analyzed to get a more detailed overview which transporters are of importance in resistance to chemotherapeutic agents in ovarian carcinoma.
Methods: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples. Genes exhibiting a significant difference between those two groups were further evaluated in 50 primary cancer samples. Data were analyzed with receiver operating characteristic (ROC) curves and multiple Wilcoxon-Mann-Whitney U-tests with Shaffer correction.
Results: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue. Expression levels of these 4 ABC transporters were further analyzed in primary ovarian cancer lesions. A significant difference between primary and recurrent tumor tissue was found in all four genes. Changes in gene expression between benign samples and primary lesions were minor and not relevant.
Conclusions: Four of the examined ABC transporters are likely to play a role in the MDR of ovarian carcinoma. Gene expression of these transporters seems only up regulated through chemotherapy. The thesis that MDR in ovarian cancer is acquired through therapy itself and not present ab initio is supported by these findings.
Copyright (c) 2009 Elsevier Inc. All rights reserved.
Similar articles
-
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 Mar;124(3):575-81. doi: 10.1016/j.ygyno.2011.11.022. Epub 2011 Nov 21. Gynecol Oncol. 2012. PMID: 22112610 Free PMC article. Clinical Trial.
-
Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.BMC Cancer. 2013 Oct 14;13:476. doi: 10.1186/1471-2407-13-476. BMC Cancer. 2013. PMID: 24124770 Free PMC article.
-
The role of ATP-binding cassette transporter genes in the progression of prostate cancer.Prostate. 2016 Apr;76(5):434-44. doi: 10.1002/pros.23137. Epub 2015 Dec 28. Prostate. 2016. PMID: 26708806
-
Future directions in the chemotherapy of ovarian cancer.Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-86-S15-90. Semin Oncol. 1997. PMID: 9346230 Review.
-
Management of platinum-sensitive recurrent ovarian cancer.Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6. doi: 10.1053/j.seminoncol.2006.03.012. Semin Oncol. 2006. PMID: 16716798 Review.
Cited by
-
EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.Cancer Res. 2020 Oct 15;80(20):4371-4385. doi: 10.1158/0008-5472.CAN-20-0458. Epub 2020 Aug 19. Cancer Res. 2020. PMID: 32816909 Free PMC article.
-
CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma.PLoS One. 2012;7(12):e52426. doi: 10.1371/journal.pone.0052426. Epub 2012 Dec 21. PLoS One. 2012. PMID: 23285037 Free PMC article.
-
Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer.Front Pharmacol. 2018 Aug 7;9:842. doi: 10.3389/fphar.2018.00842. eCollection 2018. Front Pharmacol. 2018. PMID: 30131693 Free PMC article.
-
Biological Entanglement-Like Effect After Communication of Fish Prior to X-Ray Exposure.Dose Response. 2018 Feb 15;16(1):1559325817750067. doi: 10.1177/1559325817750067. eCollection 2018 Jan-Mar. Dose Response. 2018. PMID: 29479295 Free PMC article.
-
MDR1 Gene Polymorphisms and Its Association With Expression as a Clinical Relevance in Terms of Response to Chemotherapy and Prognosis in Ovarian Cancer.Front Genet. 2020 May 26;11:516. doi: 10.3389/fgene.2020.00516. eCollection 2020. Front Genet. 2020. PMID: 32528530 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials